ArticleJournal of paediatrics and child health2026
Efficacy and Safety of Anti-Influenza Drugs in 160 Chinese Children With Influenza A: A Retrospective Study.
Article in Journal of paediatrics and child health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Baloxavir marboxil versus oseltamivir for influenza A in children aged 5 years and older: a community-based prospective cohort study.BMC infectious diseases · 2026Observational
- Efficacy and Safety of Anti-Influenza Drugs in 160 Chinese Children With Influenza A: A Retrospective Study.Journal of paediatrics and child health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn this study, we aimed to provide a comprehensive analysis of real-world implications for the therapeutic efficacy and safety of baloxavir marboxil, oseltamivir phosphate capsules and oseltamivir phosphate granules in the treatment of 160 Chinese children with influenza A.
methodsThis retrospective study included children aged 10-16 with influenza A treated at a hospital in Beijing between January 2023 and August 2024. Participants were categorised into three groups: oseltamivir capsule group (n = 56), oseltamivir granule group (n = 55) and baloxavir group (n = 49). Clinical characteristics, epidemiology, therapeutic effects (e.g., fever clearance time, total illness duration and curative rate), drug costs and adverse reactions were compared among groups.
resultsNo significant differences were found in demographics or initial symptoms (p > 0.05). Fever clearance time and total illness duration were significantly shorter in the baloxavir group compared to the oseltamivir capsule group (both p < 0.01) and the oseltamivir granule group (p < 0.01, p < 0.05) mainly in children with high fever. While the total effective rates were similar across groups, baloxavir showed a notably higher curative rate (84%, 41/49) than oseltamivir capsules (45%, 25/56) and granules (49%, 27/55) (p < 0.01). Cost analysis indicated that oseltamivir capsules were the least expensive, with baloxavir being slightly less costly than oseltamivir granules (p < 0.01).
conclusionsBaloxavir marboxil exhibited superior efficacy in reducing fever and shortening the illness duration. Its single-dose regimen enhances compliance with antiviral therapy, although it remains a relatively more expensive option. In contrast, oseltamivir granules enabled more accurate dosing, while oseltamivir capsules were the most cost-effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.